448 related articles for article (PubMed ID: 21654529)
21. Treatment strategies for patients with low bone mass: the younger postmenopausal female.
Honig S
Bull NYU Hosp Jt Dis; 2008; 66(3):240-3. PubMed ID: 18937639
[TBL] [Abstract][Full Text] [Related]
22. [Staged diagnosis in osteoporosis. Is your patient at risk for fractures?].
Seibel MJ
MMW Fortschr Med; 2001 Nov; 143(47):26-30. PubMed ID: 11791357
[TBL] [Abstract][Full Text] [Related]
23. The pathogenesis, diagnosis, investigation and management of osteoporosis.
Sandhu SK; Hampson G
J Clin Pathol; 2011 Dec; 64(12):1042-50. PubMed ID: 21896577
[TBL] [Abstract][Full Text] [Related]
24. Surgical approach to fragility fractures: problems and perspectives.
Tarantino U; Cannata G; Cerocchi I; Lecce D; Iundusi R; Celi M
Aging Clin Exp Res; 2007 Aug; 19(4 Suppl):12-21. PubMed ID: 18182887
[TBL] [Abstract][Full Text] [Related]
25. [Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].
Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
Wien Med Wochenschr Suppl; 2009; (122):1-34. PubMed ID: 19484202
[TBL] [Abstract][Full Text] [Related]
26. Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis.
Lyritis GP; Georgoulas T; Zafeiris CP
Ann N Y Acad Sci; 2010 Sep; 1205():277-83. PubMed ID: 20840284
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
28. Recognition of women at risk for fracture and intervention with fast-acting therapies.
Derman R
Int J Fertil Womens Med; 2006; 51(4):183-90. PubMed ID: 17184104
[TBL] [Abstract][Full Text] [Related]
29. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
Marcus R; Wang O; Satterwhite J; Mitlak B
J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
[TBL] [Abstract][Full Text] [Related]
30. Emerging concepts in osteoporosis and bone strength.
Rubin CD
Curr Med Res Opin; 2005 Jul; 21(7):1049-56. PubMed ID: 16004672
[TBL] [Abstract][Full Text] [Related]
31. [Evaluation of a strategy for the management of accompanying osteoporosis after inpatient treatment of fragility fractures].
Bahrs C; Türk A; Eingartner C; Weise K; Rolauffs B; Stuby F
Z Orthop Unfall; 2008; 146(1):52-8. PubMed ID: 18324582
[TBL] [Abstract][Full Text] [Related]
32. [Measurement of bone mineral density is unnecessary for monitoring of bisphosphonate treatment].
Nishida A; Ito M
Clin Calcium; 2011 Jan; 21(1):120-3. PubMed ID: 21187605
[TBL] [Abstract][Full Text] [Related]
33. [Progress in the treatment of osteoporosis].
Sugimoto T
Rinsho Byori; 2008 Oct; 56(10):887-93. PubMed ID: 19068785
[TBL] [Abstract][Full Text] [Related]
34. The role of menopausal hormone therapy in preventing osteoporotic fractures: a critical review of the clinical evidence.
Col NF; Bowlby LA; McGarry K
Minerva Med; 2005 Oct; 96(5):331-42. PubMed ID: 16227948
[TBL] [Abstract][Full Text] [Related]
35. [Daily practice using the guidelines for prevention and treatment of osteoporosis. Use of clinical risk factors for osteoporotic fractures in the evaluation of risk of future fracture].
Gorai I
Clin Calcium; 2008 Aug; 18(8):1135-40. PubMed ID: 18677051
[TBL] [Abstract][Full Text] [Related]
36. [Usefulness of FRAX and future issues in women's health].
Hashimoto K; Ishitani K; Ohta H
Clin Calcium; 2009 Dec; 19(12):1742-8. PubMed ID: 19949265
[TBL] [Abstract][Full Text] [Related]
37. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology, etiology, and diagnosis of osteoporosis.
Lane NE
Am J Obstet Gynecol; 2006 Feb; 194(2 Suppl):S3-11. PubMed ID: 16448873
[TBL] [Abstract][Full Text] [Related]
39. Is there a place for bone turnover markers in the assessment of osteoporosis and its treatment?
Devogelaer JP; Boutsen Y; Gruson D; Manicourt D
Rheum Dis Clin North Am; 2011 Aug; 37(3):365-86, v-vi. PubMed ID: 22023897
[TBL] [Abstract][Full Text] [Related]
40. Management of postmenopausal osteoporosis.
Andreopoulou P; Bockman RS
Annu Rev Med; 2015; 66():329-42. PubMed ID: 25386933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
